Re-examining FDA Botanical Drug Regulation: Reflections and Implications for TCM Quality Regulation and Evidence Evaluation —Based on the 2026 RFI and the Joint FDA/EMA Workshop

doi:10.3969/j.issn.1673-5390.2026.10.002

QIAN Zhong-zhi, SONG Zong-hua

China Food Drug Administration ›› 2026, Vol. 0 ›› Issue (10) : 18-27.

PDF(1803 KB)

China Food Drug Administration ›› 2026, Vol. 0 ›› Issue (10) : 18-27. DOI: 10.3969/j.issn.1673-5390.2026.10.002

Special Report

Re-examining FDA Botanical Drug Regulation: Reflections and Implications for TCM Quality Regulation and Evidence Evaluation —Based on the 2026 RFI and the Joint FDA/EMA Workshop

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 0(10): 18-27 https://doi.org/10.3969/j.issn.1673-5390.2026.10.002

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(1803 KB)

Accesses

Citation

Detail

Sections

Recommended

Please choose a citation manager

Content to export